miR-22 represses cancer progression by inducing cellular senescence by Xu, Dan et al.
JCB: Article
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 193 No. 2  409–424
www.jcb.org/cgi/doi/10.1083/jcb.201010100 JCB 409
Correspondence to Hidetoshi Tahara: toshi@hiroshima-u.ac.jp
Abbreviations used in this paper: cont miR, control miRNA; HPA, hybridization   
protection assay; hTERT, human telomerase reverse transcriptase; LNA, locked   
nucleic acid; miRNA, microRNA; PDL, population doubling level; pRb, retino-
blastoma  protein;  SA--gal,  senescence-associated  -galactosidase;  SAHF,   
senescence-associated heterochromatin foci; SA-miRNA, senescence-associated 
miRNA; UTR, untranslated region; WT, wild type.
Introduction
Tumor progression is a multistep process wherein several de-
fined events are common to cancer cells, such as uncontrolled 
proliferation and invasion (Hahn and Weinberg, 2002). Cellular 
senescence is characterized by an irreversible arrest of cell pro-
liferation, so that it can prevent the aberrant and unlimited pro-
liferation of tumor cells (Campisi, 2005). Senescent cells exhibit 
enlarged morphological changes and less motility than young 
cells, which may contribute to the suppression of cell migration, 
invasion, and metastasis (Chen et al., 2000). Oncogene-induced 
senescence is a cellular response, which can occur in vivo and 
provides a bona fide barrier to tumorigenesis (Narita and Lowe, 
2005). Oncogene-induced senescence was found in premalig-
nant tumors but not in more advanced malignant tumors (Braig 
et al., 2005; Collado et al., 2005). Therefore, cellular senescence 
acts as an important barrier to cancer and plays an important 
role in tumor suppression.
microRNAs (miRNAs) are a class of naturally occurring 
small noncoding RNAs that negatively regulate the stability and 
translation of target protein–coding mRNAs at the 3 untranslated 
region (UTR). miRNAs typically target a cluster of genes rather 
than one specific gene (Bartel, 2004), a characteristic which allows 
them to play critical roles in a variety of biological processes 
such as cell proliferation, differentiation, apoptosis, and carcino-
genesis (He and Hannon, 2004). Recently, a growing number 
of studies have documented the miRNA expression profiles in 
human cancers (Calin and Croce, 2006), suggesting that miRNAs 
emerge as novel biomarkers for various cancers. However, there 
is currently little information about miRNA profiling studies 
and biological effects of miRNAs in cellular senescence.
The senescence program is established and maintained by 
p53 and retinoblastoma protein (pRb) tumor suppressor pathways. 
The requirements of p53 and pRb for the induction of cellular 
senescence vary in their prominence depending on the genetic 
context, species, and cell type (Adams, 2007; Schmitt, 2007; 
C
ellular senescence acts as a barrier to cancer pro-
gression, and microRNAs (miRNAs) are thought 
to be potential senescence regulators. However, 
whether  senescence-associated  miRNAs  (SA-miRNAs) 
contribute to tumor suppression remains unknown. Here, 
we report that miR-22, a novel SA-miRNA, has an impact 
on tumorigenesis. miR-22 is up-regulated in human senes-
cent fibroblasts and epithelial cells but down-regulated 
in  various  cancer  cell  lines.  miR-22  overexpression 
induces growth suppression and acquisition of a se-
nescent phenotype in human normal and cancer cells.   
miR-22 knockdown in presenescent fibroblasts decreased 
cell size, and cells became more compact. miR-22–induced 
senescence also decreases cell motility and inhibits cell 
invasion in vitro. Synthetic miR-22 delivery suppresses 
tumor growth and metastasis in vivo by inducing cellular 
senescence in a mouse model of breast carcinoma. We 
confirmed that CDK6, SIRT1, and Sp1, genes involved in 
the senescence program, are direct targets of miR-22. 
Our study provides the first evidence that miR-22 restores 
the cellular senescence program in cancer cells and acts 
as a tumor suppressor.
miR-22 represses cancer progression by inducing 
cellular senescence
Dan Xu,
1 Fumitaka Takeshita,
3 Yumiko Hino,
1 Saori Fukunaga,
1 Yasusei Kudo,
2 Aya Tamaki,
1 Junko Matsunaga,
1 
Ryou-u Takahashi,
3 Takashi Takata,
2 Akira Shimamoto,
1 Takahiro Ochiya,
3 and Hidetoshi Tahara
1
1Department of Cellular and Molecular Biology and 
2Department of Oral Maxillofacial Pathobiology, Graduate School of Biomedical Science, Hiroshima University, 
Minami-ku, Hiroshima 734-8553, Japan
3Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan
© 2011 Xu et al.  This article is distributed under the terms of an Attribution–Noncommercial–
Share Alike–No Mirror Sites license for the first six months after the publication date (see 
http://www.rupress.org/terms). After six months it is available under a Creative Commons 
License  (Attribution–Noncommercial–Share  Alike  3.0  Unported  license,  as  described  at 
http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
YJCB • VOLUME 193 • NUMBER 2 • 2011   410
These include miR-22, miR-34a, miR-125a-5p, miR-24-2*, and 
miR-152, several of which, namely miR-34a and miR-125a-5p, 
are closely associated with senescence-like growth arrest and 
metastasis in cancer cells (Tazawa et al., 2007; Li et al., 2009; 
Wang et al., 2009). Here, we focused on miR-22 and evalu-
ated the expression of miR-22 in young and senescent human 
diploid fibroblast strains. Quantitative (q) RT-PCR analysis 
confirmed that miR-22 expression was increased in senescent 
TIG-3 and other fibroblasts and even up-regulated by more than 
fivefold in senescent MRC-5 cells (Fig. 1 B). These findings 
suggest that miR-22 up-regulation is universal in senescent   
human fibroblasts.
To investigate the involvement of miR-22 in cellular senes-
cence in human fibroblasts, we enforced miR-22 expression by 
introduction of mature miR-22 duplex into young fibroblasts. We 
first examined miR-22 expression level by qRT-PCR analysis at 
day 6 after direct transfection with miR-22 duplex into young 
MRC-5 cells (Fig. 1 C). Compared with the endogenous level of 
miR-22 in the senescent MRC-5 cells (fivefold higher than young 
cells), miR-22 was up-regulated by 2.9-fold (1 nM), 4-fold 
(5 nM), and 15.7-fold (10 nM) in MRC-5 cells, relative to control 
miRNA  (cont  miR)  in  each  transfection  group.  Furthermore, 
miR-22 also increased SA--gal activity (Fig. 1 D), a well known 
senescence cytosolic biomarker, in a transfection dose-dependent 
manner, whereas cont miR did not induce SA--gal activity. These 
results imply that up-regulation of miR-22 expression is signifi-
cant for the induction of senescence phenotypes. Because the ces-
sation of cell proliferation is a hallmark of cellular senescence, we 
examined whether cell proliferation is altered by overexpression 
of miR-22. We observed that transfection of 10 nM miR-22 caused 
a remarkable inhibition of cell proliferation compared with that of 
cont miR (Fig. 1 E), and this growth inhibition by miR-22 is in a 
dose-dependent  manner  (not  depicted).  Senescence-associated 
heterochromatin foci (SAHF) formation is thought to be a senes-
cence nuclei biomarker and is often observed in senescent fibro-
blasts (Dimri et al., 1995; Narita et al., 2003; Adams, 2007). We 
observed obvious SAHF formation in miR-22–transfected cells, 
and the percentage of SAHF-positive cells was significantly in-
creased by miR-22 overexpression and was also increased in senes-
cent MRC-5 cells (Fig. 1 F). This result is not cell type specific 
because other fibroblasts, such as IMR90, transfected with miR-22 
appeared to be senescence phenotypes (unpublished data).
To ensure that the function of mature miRNA is not at a 
supraphysiological level, we repeated these experiments using a 
stable  miRNA  vector  that  mimics  miRNA  biological  pro-
cessing. Pre–miR-22 lentiviral construct (Lenti-Pre22), stably 
expressing miR-22 precursor in its native context, was used to 
study the effect of miR-22 on cellular senescence in MRC-5   
fibroblasts. Lenti-Pre22–infected cells exhibited the enlarged 
senescence morphology and SA--gal–positive staining (Fig. 2 A). 
Compared with Lentiviral empty vector (Lenti-C), Lenti-Pre22 
infection significantly increased SA--gal activity and caused 
growth arrest in MRC-5 cells (Fig. 2, A and B), which is similar 
to the effect of mature miR-22. Collectively, these results sug-
gest that miR-22 is associated with cellular senescence, accom-
panied by the induction of major specific senescence-associated 
markers in human diploid fibroblasts.
Haferkamp et al., 2009). Recently, various studies have indi-
cated that some miRNAs, such as miR-34a and miR-20a, induce 
senescence-like growth arrest through regulating cell cycle genes 
and senescence-associated genes involved in the p53 and/or 
pRb pathway (Tazawa et al., 2007; Poliseno et al., 2008; Sun   
et al., 2008). Such miRNAs play a direct role in senescence 
and are called senescence-associated miRNAs (SA-miRNAs; 
Lafferty-Whyte et al., 2009).
In the present study, we attempted to screen SA-miRNAs 
that control cellular senescence in human fibroblasts, and we 
report here that miR-22 is a novel SA-miRNA that functions in 
mediating cellular senescence. We studied the role of miR-22 
in cellular senescence using human normal cells and cancer cell 
lines as an in vitro culture system as well as an in vivo mouse 
breast  tumor  model.  Upon  senescence,  cells  become  flat-
tened and enlarged and exhibit biochemical changes such as   
the increased perinuclear activity of senescence-associated   
-galactosidase (SA--gal; Dimri et al., 1995; Narita et al., 2003). 
Another critical event during the cellular senescence process is 
a decrease in cell growth and cell motility. We found a wide-
spread decrease of miR-22 expression in various human cancer 
cell lines. Introduction of miR-22 into cancer cells inhibits cell 
proliferation, accompanied by senescence-like cell morphology 
and a decrease in cell motility and invasiveness. We predicted 
the putative direct targets of miR-22 by the computational pre-
diction of targets based on sequence match to the miRNA. 
We identified three targets, including CDK6, Sp1, and SIRT1, 
which are directly regulated by miR-22. Furthermore, silenc-
ing of these targets resulted in growth arrest and increased 
SA--gal activity, accompanied by pRB dephosphorylation. 
We confirmed that miR-22 regulated the pRb pathway of cellular 
senescence through targeting of CDK6 and SIRT1. Ectopic ex-
pression of CDK6, SIRT1, or Sp1 could partially rescue the se-
nescence phenotypes in miR-22–transfected cells. Significantly, 
miR-22 injection suppresses tumor growth and metastasis in 
vivo by induction of senescence in breast tumor, suggesting that 
SA-miRNA miR-22 acts as an important barrier to cancer and 
plays an important role in tumor suppression. Our findings pro-
vide new insight for the role of SA-miRNAs between cellular 
senescence and tumorigenesis.
Results
miR-22 overexpression induces cellular 
senescence in human fibroblasts
To identify miRNAs that control cellular senescence, we ana-
lyzed miRNA expression profiling by miRCURY locked nu-
cleic acid (LNA) miRNA array in young and senescent TIG-3   
fibroblasts (Fig. 1 A). We found that a set of altered expression 
miRNAs has been reported to be involved in cell growth and   
tumorigenesis (Fig. 1 A and Table S1). Among them, the majority 
of antigrowth miRNAs were expressed two– to fourfold more 
in senescent TIG-3 cells than in young cells. To confirm and 
validate the results, we performed 3D-Gene miRNA microarray 
to evaluate miRNA expression levels. Two kinds of microarray 
analysis showed that five miRNAs are uniformly up-regulated 
by twofold or greater in senescent compared with young cells. 411 miR-22 induces cellular senescence • Xu et al.
vector (anti-C)–treated cells (Fig. 2 D). For presenescent MRC-5 
cells, stable knockdown of miR-22 caused obvious morphologi-
cal changes, exhibiting small and thin morphology (Fig. 2 C, 
GFP-labeled cells marked with arrows), whereas those cells that 
failed to be infected exhibited enlarged senescent morphology 
(Fig. 2 C, white triangles) within the same field under the fluores-
cent microscope. Presenescent MRC-5 cells entered senescence 
and demonstrated obvious SA--gal staining as time passed. 
Anti-22–infected presenescent MRC-5 cells maintained small 
and thin morphology for >2 wk with a decreased percentage of 
SA--gal–positive cells (Fig. 2 E), and there appeared to be a 
significant  decrease  in  cell  size  and  percentage  of  cells   
Furthermore, we wondered how knockdown of miR-22 
impacts cellular senescence phenotypes and whether a reduced 
expression of miR-22 would impede the progression of senes-
cence and extend the life span in fibroblasts. miRZip anti–miR-22 
expression lentivector (anti-22), which can stably express anti–
miR-22 and provide permanent miR-22 inhibition, was used to 
infect young (44 population doubling level [PDL]) and pre-
senescent (54 PDL) MRC-5 cells. We observed that Leni-Pre22–
infected young MRC-5 cells demonstrated enlarged senescent 
morphological changes (Fig. 2 C, GFP-labeled cells marked 
with yellow arrowheads). In contrast, anti-22–infected young 
MRC-5 cells seemed smaller and younger than anti-22 empty 
Figure 1.  miR-22 is up-regulated in senescent human fibroblasts, mediating cellular senescence. (A) miRNA expression profile of TIG-3 fibroblasts was 
analyzed by miRNA microarray, presented as fold changes in miRNA expression between TIG-3S (senescent) and young (Y) cells. A set of altered ex-
pression miRNAs is indicated by red columns (see Table S1). RQ, relative quantitation. (B) Relative quantitation of miR-22 expression in different PDLs of 
fibroblasts was analyzed by qRT-PCR analysis. miR-22 expression levels in human fibroblasts were indicated, relative to those in TIG-3 (42 PDL) set at 1 in 
the left histogram and MRC-5 (43 PDL) set at 1 in the right histogram. U6 was used as an internal normalization control. The dashed line represents the 
threshold of expression level (twofold vs. TIG-3 42 PDL). (C and D) MRC-5 cells were transfected with cont miR or mature miR-22 (miR-22) for 6 d at indi-
cated concentration. (C) qRT-PCR analysis shows the relative quantitation of miR-22 expression (vs. cont miR) in each transfection group. miR-22 expression 
levels in miR-22–transfected MRC-5 cells were indicated, relative to that in cont miR–transfected cells set at 1. U6 was used as an internal normalization 
control. (D) SA--gal activity was presented by the percentage of SA--gal–positive cells, which was indicated in different dose groups. (E) Cell prolifera-
tion assay was performed after transfection of 10 nM miR-22 or cont miR, and cells were counted for the indicated days. Each value was determined in 
triplicate. **, P < 0.01. (F) Representative photos for SAHF formation in MRC-5 cells at day 6 after transfection. Images were taken with fluorescence 
microscopy. Enlarged images of the boxed area from the top are shown in the bottom. SAHF formation was quantified by counting 200 cells from >10 
random fields, and the results were shown in the right histogram in contrast to MRC5S (senescent; 58 PDL). Data in all the panels represent mean ± SEM (n = 3). 
*, P < 0.05; **, P < 0.01. Bars, 20 µm.JCB • VOLUME 193 • NUMBER 2 • 2011   412
of irreversible growth arrest in senescent cells. These findings 
suggest the requirement of miR-22 in mediating senescence and 
indicate that miR-22 inhibition is indeed an obstacle for the pro-
gression of senescence in fibroblasts.
distributed in a large-sized group (Fig. 2 F), compared with   
senescent anti-C–treated cells. Although stable knockdown of 
miR-22 exhibited neither the promotion of cell proliferation nor 
the extension of the life span (not depicted), this might be a result 
Figure 2.  Stable expression and knockdown 
of  miR-22  affect  senescence  phenotypes  in 
MRC-5 cells. (A) Cell morphology and SA--
gal activity were analyzed by phase-contrast 
microscopy at day 6 after infection with empty 
vector  (Lenti-C)  or  premiR-22  (Lenti-Pre22). 
The  percentage  of  SA--gal–positive  cells  is 
presented in the right histogram. (B) Cell pro-
liferation assay was performed after infection 
of Lenti-Pre22, and cells were counted for the 
indicated days, compared with control cells. 
Each  value  was  determined  in  triplicate.   
**, P < 0.01. (C) Cell morphology was ana-
lyzed with fluorescence microscopy at day 6 
after  infection.  GFP-labeled  cells  indicate  in-
fected cells (middle). Yellow arrowheads and 
white arrows depict miR-22 overexpression in 
young MRC-5 cells and miR-22 knockdown in 
presenescent MRC-5 cells, respectively. Those 
cells that failed to be infected are marked with 
white triangles. (D) Cell morphology of anti-
22–infected young MRC-5 was analyzed by 
phase-contrast microscopy and compared with 
anti-C. (E) Presenescent MRC-5 cells infected 
with anti-C or anti-22 were subjected to SA--
gal assay at days 6 and 14 after infection. The 
percentage of SA--gal–positive cells at day 
14 after infection is presented in the bottom 
panels. (F) Cell morphology area and cell size 
distribution  were  analyzed  using  ImageJ  by 
counting GFP-expressed presenescent MRC-5 
cells after infection with anti-C or anti-22 for 
6 d. Cell morphology area index represents 
cell  size  (micrometers  squared).  Cell  size 
distribution  was  divided  into  three  groups: 
0–500, 500–1,000, and 1,000 m
2 and up. 
Data in all the panels represent mean ± SEM   
(n = 3). **, P < 0.01. Bars: (A, D, and E) 50 µm;   
(C) 20 µm.413 miR-22 induces cellular senescence • Xu et al.
that miR-22 expression was increased in Lenti-Pre22–infected 
SiHa cells (Fig. 4 G) close to the expression level of miR-22 
(10 nM). Lenti-Pre22 also induced senescence-specific mor-
phological changes, increased SA--gal activity, and inhibited 
cell growth (Fig. 4, H and I), indicating the induction of cellular 
senescence by miR-22 overexpression in SiHa cells.
Moreover, we did not observe any significant increase in 
TUNEL-positive  apoptotic  cells  in  miR-22–transfected  SiHa 
and MDA-D3 cells (Fig. S1, A and B). These findings suggest 
that the growth suppression induced by miR-22 overexpression 
was caused by the induction of G1 arrest in cellular senescence 
rather than apoptosis. In reverse, miR-22 knockdown in cancer 
cells resulted in various morphological changes and differential 
timing of apoptosis in different cell lines. Anti-22–infected SiHa 
cells appeared to be small and underwent apoptosis at day 6 after 
infection (Fig. S1 C), whereas MDA-D3 cells became rounded 
and apoptotic cells were observed in anti-22–infected cells from 
the third day after infection (Fig. S1 D), which might be be-
cause the timelines for the progression of different cells through 
apoptosis vary in different cell lines (Jessel et al., 2002).
Various findings have suggested the critical role of telo-
mere shortening in contributing to cellular senescence in human 
cells (Deng et al., 2008). Telomeric 3-overhang (G-tail) is essen-
tial for proper telomere function (Tahara et al., 2005). Here, over-
expression of miR-22 had no effect on the length of either total 
telomere or G-tail (Fig. S2), indicating that miR-22–induced 
senescence is possibly independent of telomere shortening.
SIRT1, Sp1, and CDK6 are direct targets 
of miR-22
miRNAs are known to suppress hundreds of mRNA targets, re-
sulting in global changes in the cellular phenotype of cells (He 
and Hannon, 2004). We therefore make an effort to identify po-
tential targets for miR-22 using both in silico and experimental 
approaches. We used a consensus approach with three widely 
used types of software (miRanda, TargetScan, and PicTar) to 
perform the target prediction. After overlapping prediction analy-
sis, we screened those genes that were down-regulated upon se-
nescence and implicated in cell growth and cell cycle regulation. 
Based on this, SIRT1, Sp1, and CDK6 were selected to be puta-
tive miR-22 target genes. The mRNAs of SIRT1 and Sp1 con-
tain putative binding sites for miR-22 in their 3-UTRs, and 
each site is broadly conservative among mammals. CDK6 mRNA 
contains three miR-22 binding sites in the 3-UTR, whereas it is 
different in conservation for each site (Fig. 5 A).
To address those genes directly regulated by miR-22, we 
performed luciferase reporter assay. We constructed pmirGLO 
full-length 3-UTR of both SIRT1 and Sp1. Because the full-
length 3-UTR of CDK6 is too long (10 kbp), human CDK6 
3-UTR containing three binding sites (6 kbp) was amplified 
and cloned into pmirGLO vector. Furthermore, to study which 
site in the 3-UTR of each gene is important, we engineered 
luciferase reporters that have exact binding sites of 3-UTRs of 
these genes including the wild type (WT) and two mutant UTRs 
(Mut1 and Mut2), as shown in Fig. 5 C. In SiHa and MDA-D3 
cells, miR-22 significantly reduced the luciferase activities of 
the full-length 3-UTR (Fig. 5 B) or WT SIRT1, SP1, and CDK6 
miR-22 overexpression induces growth 
suppression and senescence-like 
phenotypes in human breast epithelial and 
cancer cells
Senescence has been most widely studied in fibroblasts in vitro 
but is also well defined in other cell types, such as epithelial cells 
which are the origin of most carcinoma (Narita et al., 2003).   
Expression of human telomerase reverse transcriptase (hTERT) 
in certain cell types has been shown to extend cellular life span 
without malignant transformation. To investigate the effect of 
miR-22 on cellular senescence in human epithelial cells, we 
used hTERT-infected HMEC184 (184hTERT) cells that possess 
the unlimited proliferation capacity of HMEC184 cells and are 
regarded as immortalized. We found that miR-22 was expressed 
higher by >2.5-fold in senescent HMEC184 (22 PDL) than in 
184hTERT cells that have a similar miR-22 expression level 
to that of normal young HMEC184 (Fig. 3 A). Compared with 
immortalized 184hTERT cells, a widespread decrease in miR-22 
level was observed in various human cancer cells (Fig. 3 A), 
indicating that miR-22 may have an intrinsic function in tumor 
suppression associated with various human malignancies.
To test this notion, we first evaluated the effect of miR-22 
on cell growth and SA--gal activity in human breast epithelial 
cells and two breast cancer cell lines. We found that miR-22 sig-
nificantly inhibited cell growth in 184hTERT, MCF7, and MDA-
MB-231-luc-D3H2LN (called MDA-D3 for short; Fig. 3 B). We 
noted that mature miR-22 caused remarkable and characteristic 
morphological alterations, including enlarged cellular size and 
a flattened shape (Fig. 3 C), and significantly increased SA- 
-gal activity in the three cells (Fig. 3 D). Furthermore, we con-
firmed that overexpression of premiR-22 in MDA-D3 cells also 
significantly induced senescence-specific morphological changes, 
increased SA--gal activity (Fig. 3 E), and inhibited cell growth 
(Fig. 3 F), similar to the effect of mature miR-22.
The marked induction of senescence by miR-22 in human 
breast cancer cells prompted us to investigate whether miR-22 
induces cellular senescence in other human cancer cells. There-
fore, we further studied the effect of miR-22 in the human cervi-
cal carcinoma cell line SiHa. We confirmed the dose-dependent 
increase in miR-22 expression level (Fig. 4 A) and SA--gal 
activity (Fig. 4 B) after direct transfection of miR-22 in SiHa 
cells, whereas cont miR affected neither the cell growth nor 
the SA--gal activity. Introduction of 10 nM miR-22 resulted 
in cells exhibiting a senescence-like flattened shape and SA-
-gal–positive staining (Fig. 4 C), and it induced remarkable 
growth suppression compared with that of cont miR (Fig. 4 D). 
Because senescent cells never reenter the cell cycle and appear 
to decrease in DNA synthesis, we performed FACS analysis and 
quantity analysis of BrdU incorporation in SiHa cells. miR-22 
overexpression induced cell cycle arrest at G1 phase, accompa-
nied by the decrease in percentages of S phase (Fig. 4 E). The 
inhibitory effect of miR-22 on cell cycle progression has also 
been recently reported in other cancer cells (Ting et al., 2010). 
Furthermore, miR-22 resulted in the decrease of BrdU incorpora-
tion in comparison with cont miR or miR-34a (Fig. 4 F), indi-
cating impaired DNA replication in miR-22–transfected cells 
during the S phase of the cell cycle. In addition, we confirmed JCB • VOLUME 193 • NUMBER 2 • 2011   414
Western blot analysis showed that overexpression of miR-22 
markedly down-regulated SIRT1, SP1, and CDK6 in SiHa and 
MDA-D3 cells (Fig. 5 F). Moreover, we confirmed that SIRT1 and 
CDK6 were down-regulated in senescent MRC-5 fibroblasts 
and HMEC184 epithelial cells, accompanied by a decrease in pRB 
phosphorylation at ser807/811 (Fig. 5 G). This indicates that SIRT1 
and CDK6 are senescence-associated genes that are involved in 
cellular senescence possibly through the pRb pathway. Sp1 was 
not detected because of its low expression level in these cells.
(site 1 and site 3) reporters (Fig. 5 D), compared with the nega-
tive cont miR. In contrast, neither Mut1 (deletion of seed re-
gion) nor Mut2 of mutant reporters was repressed by miR-22, 
which indicates that these target sites directly mediate the re-
pression (Fig. 5 E). In addition, this down-regulation was not 
seen in WT construct of CDK6 site 2, possibly because of 
poorly conserved sites among mammals. These results provide 
experimental evidence that miR-22 can directly repress transla-
tion initiation of SIRT1, SP1, and CDK6.
Figure 3.  Overexpression of miR-22 induces 
senescence-like  phenotypes  in  human  breast 
epithelial and breast cancer cells. (A) qRT-PCR 
analysis  shows  relative  quantitation  of  miR-22   
expression level (vs. 184hTERT) in human epi-
thelial and various cancer cells. Expression levels 
of miR-22 in various cells were relative to that 
in 184hTERT cells set at 1. U6 was used as an 
internal normalization control. The dashed line 
represents the threshold of expression level (0.5-
fold vs. 184hTERT). (B) Cell proliferation assay   
was performed after transfection of miR-22, and 
cells  were  counted  for  the  indicated  days, 
compared with control cells. Each value was 
determined in triplicate. *, P < 0.05. (C–E) Cell 
morphology and SA--gal activity were ana-
lyzed by phase-contrast microscopy at day 6 
after transfection (C and D) or infection (E) in 
indicated cells. SA--gal activity was presented 
by the percentage of SA--gal–positive cells. 
(F) Cell proliferation assay was performed at 
day 6 after MDA-D3 cells were infected with 
Lenti-Pre22 and compared with control cells. 
Data in all the panels represent mean ± SEM 
(n = 3). *, P < 0.05; **, P < 0.01. Bars, 50 µm.415 miR-22 induces cellular senescence • Xu et al.
the  siRNAs  against  SIRT1  and  CDK6  knocked  down  the 
expression of SIRT1 and CDK6 and caused dephosphoryla-
tion of pRB at ser807/811 (Fig. 6, C and E), which was also   
induced by either mature miR-22 or premiR-22 overexpres-
sion in various different cells (Fig. 6, D and F). In addition, 
Furthermore, silencing of these target genes by siRNAs 
resulted in growth arrest (Fig. 6 A) and increased SA--gal 
activity in MRC-5 fibroblasts and MDA-D3 cells (Fig. 6 B), 
as well as morphological changes (not depicted), similar with 
miR-22–induced senescence phenotypes. We confirmed that 
Figure 4.  Overexpression of miR-22 induced 
cellular senescence, cell cycle G1 arrest, and 
the  decrease  in  BrdU  incorporation  in  SiHa 
cells.  (A  and  B)  SiHa  cells  were  transfected 
with cont miR or miR-22 at the indicated con-
centration for 6 d. qRT-PCR results show the 
relative level of miR-22 expression to cont miR 
in each transfection group (A). SA--gal activ-
ity was presented by the percentage of SA- 
-gal–positive cells (B). (C) Cell morphology and 
SA--gal  activity  were  analyzed  by  phase-
contrast microscopy at day 6 after transfection 
of 10 nM miR-22 or cont miR. (D) Cell pro-
liferation assay was performed after transfec-
tion of 10 nM miR-22, and cells were counted 
for the indicated days, compared with control 
cells. Each value was determined in triplicate.   
**, P < 0.01. (E) Cell cycle analysis was per-
formed at 48 h after transfection. The percent-
age of G1, S, and G2 are demonstrated as 
shown.  The  histogram  displays  the  relative 
changes of G1 and G2 phase compared with 
S  phase.  (F)  BrdU  quantitative  analysis  was 
performed at 72 h after transfection, presented 
by  the  percentage  of  BrdU  incorporation.   
(G) Stable expression of miR-22 (Lenti-Pre22) 
was evaluated by qRT-PCR analysis, presented 
by the relative quantitation of miR-22 expres-
sion level at day 6 after infection. Expression 
level of miR-22 in Lenti-Pre22–transfected cells 
was relative to that in Lenti-C–transfected cells 
set at 1. U6 was used as an internal normal-
ization control. (H) Cell morphology and SA--
gal activity were analyzed by phase-contrast 
microscopy at day 6 after infection. The per-
centage of SA--gal–positive cells is presented 
in  the  right  histogram.  (I)  Cell  proliferation 
assay was performed at day 6 after infection 
with  Lenti-Pre22  and  compared  with  control 
cells. Data in all the panels represent mean ±   
SEM (n = 3). *, P < 0.05; **, P < 0.01.   
Bars, 50 µm.JCB • VOLUME 193 • NUMBER 2 • 2011   416
Figure 5.  SIRT1, Sp1, and CDK6 are direct targets of miR-22. (A) Summary of miR-22 target sites in the 3-UTR of SIRT1, Sp1, and CDK6. H, human;   
P, chimp; M, mouse; R, rat; D, dog. The underlined bold nucleotides indicate target sites. (B–E) Target validation of SIRT1, Sp1, and CDK6 was confirmed in 
the luciferase reporter assay. (C) Scheme of the luciferase reporter constructs containing conserved miR-22 target sites (WT), deletion of seed region (Mut1), 
or base substitution of seed region (Mut2) was indicated using SIRT1 as an example. The seed region is italic bold, and point mutations are boxed in the 
seed region. Each construct, including full-length 3-UTR (B), WT (D), or Muts (E), was cotransfected with miR-22 or cont miR into SiHa or MDA-D3 cells. Rela-
tive luciferase level = (Sluc/Srenilla)/(Cluc/Crenilla) in relative light units (RLUs). Sluc, RLUs of firefly luciferase activity in miR-22–transfected sample. Srenilla, RLUs of 
renilla luciferase activity in miR-22–transfected sample. Cluc, RLUs of firefly luciferase activity in cont miR–transfected groups. Crenilla, RLUs of renilla luciferase 417 miR-22 induces cellular senescence • Xu et al.
activity in cont miR–transfected groups. PC, positive control. (F) Representative Western blot analysis of SIRT1, Sp1, and CDK6 in SiHa and MDA-D3 cells 
transfected with cont miR (C) and mature miR-22 (22) at 72 h after transfection. (G) The expression levels of SIRT1, CDK6, and pRB phosphorylation in MRC-5 
and HMEC184hTERT cells were analyzed by immunoblotting. -actin was used as a loading control and the relative density of bands was densitometrically 
quantified. Y, young; S, senescent; hTERT, 184hTERT. Data in all the panels represent mean ± SEM (n = 3). *, P < 0.05; **, P < 0.01.
 
p53 protein level did not change in MRC-5 and MDA-D3 
cells,  but  p53  expression  is  up-regulated  in  miR-22–trans-
fected SiHa cells (Fig. 6 F). These findings indicate that miR-22 
may affect the pRb pathway of cellular senescence by targeting 
SIRT1 and CDK6.
Lastly, we attempted to determine whether overexpression 
of any of the three genes could rescue the senescence phenotype 
in cells overexpressing miR-22. We forced SiHa or MDA-D3 cells 
to express SIRT1, Sp1, or CDK6 using plasmid constructs lacking 
3-UTRs of these genes. Indeed, miR-22–induced cell growth re-
pression and SA--gal activity were partially rescued by the intro-
duction of SIRT1, CDK6, or Sp1 in either SiHa cells (Fig. 6,   
G and H) or MDA-D3 cells (not depicted), although it seemed 
weak for the effect of Sp1 overexpression on cell growth, which 
might be because of the indirect role of Sp1 in the pRb pathway of 
senescence. Collectively, these findings suggest that SIRT1, Sp1, 
and CDK6 play an important role in miR-22–induced senescence.
miR-22 alters tumor cell morphology and 
suppresses cell invasiveness in vitro
Changes in cell morphology are important parameters of cancer 
invasion  and  metastasis.  We  performed  high  content  analysis   
using Operetta to measure the morphology area of all the cells 
transfected with miR-22, miR-34a, or cont miR on each well of a 
96-well plate (Fig. 7 A and Fig. S3 B) and analyzed cell size dis-
tribution (Fig. 7 B). We found there were significant differences in 
cell size distribution between miR-22–treated cells and other cells. 
miR-22 remarkably increased cell morphology area up to 1.6-fold 
overall and raised percentages of cells distributed in large cell size 
groups in comparison with cont miR or miR-34a, revealing that 
miR-22 triggers senescence morphological changes in tumor 
cells. In addition, miR-22–treated cells contain enhanced actin 
stress fibers (Fig. 7 A) similar to senescent fibroblasts, indicating 
that those cells are less motile (Chen et al., 2000; Belguise et al., 
2005). We observed that senescent fibroblasts and Lenti-Pre22–
infected cancer cells exhibiting large flattened senescence-like 
morphology appeared to decrease in cell movement (Fig. S4 and 
Videos 1–4, large GFP-positive cells), indicating that miR-22– 
induced senescence morphology in cancer cells could be attrib-
uted to the suppression of cell motility. Matrigel invasion assay 
showed that miR-22 significantly reduced the number of invaded 
cells in SiHa and MDA-D3 cells (Fig. 7 C), indicating that the in-
vasive potential of cancer cells was severely affected by miR-22. 
Therefore, the inhibition of cancer cell invasion by miR-22 may 
be a result of the induction of cellular senescence.
miR-22 inhibits tumor growth and 
metastatic potential of aggressive breast 
cancer in vivo
We next asked whether miR-22 overexpression would also 
induce senescence in vivo and suppress tumor growth and   
metastasis in vivo. Using breast cancer tumor models, the cont 
miR–treated mice showed the apparent presence of primary 
tumor, whereas those injected with miR-22 complex exhibited 
no increase in the luminescence of primary tumor during the 
same observation period (Fig. 8 A, left). Judging from photon 
count between the cont miR– and miR-22–treated groups at the 
two points of the experiment, miR-22 treatment resulted in a 
mean decrease in tumor growth of 41.3% at day 39 (P = 0.04; 
not depicted) and 66% at day 46 (P = 0.005; Fig. 8 A, right), 
suggesting that miR-22 exerted significant tumor growth sup-
pression in vivo. We also compared tumor metastasis with im-
portant organs in the two groups and were surprised to find that 
miR-22 delivery resulted in the inhibition of distant metastasis 
in the liver, kidney, spleen, stomach, and small intestine (Fig. 8 B). 
There were significant differences in the whole body of mice 
between the cont miR– and miR-22–treated groups on day 46 
(P = 0.004), indicating the inhibition of metastasis by injection 
with miR-22 in vivo.
We also confirmed that synthetic miR-22 was delivered 
into primary tumor by quantitation of the miR-22 level in tumor 
(Fig. 8 C). Furthermore, the number of SA--gal–positive cells 
in miR-22–treated tumor dramatically increased, correlated with 
the amount of miR-22 in tumor (Fig. 8 D). In addition, we did 
not observe SA--gal–positive cells in nontumor cells such as 
vascular endothelial cells and other stroma cells of mice. More-
over, we found that the morphologies of the tumors were differ-
ent; the cells in cont miR–treated groups were densely packed 
and slightly elongated, whereas those in miR-22–treated groups 
were larger and more irregularly shaped (Fig. 8 E). Pathologi-
cally, vacuolation and nuclear pyknosis associated with degrada-
tion of tumor cells were found in miR-22–treated tumor tissues. 
Therefore, it is possible that induction of cellular senescence in 
tumor cells may result in these pathological changes.
The progression toward metastasis formation requires prolif-
eration of tumor cells at primary sites and distant sites. Notably, 
the expression of Ki-67 in miR-22–treated groups was signifi-
cantly lower than that in cont miR–treated groups and nontreated 
groups (Fig. 8 F), indicating the inhibition of cell proliferation 
in tumor tissues treated with miR-22. Together, these findings 
suggest that miR-22 significantly induced cellular senescence 
in breast cancer in vivo, consequently inhibiting tumor growth 
and metastasis in vivo.
Discussion
The present study for the first time reported the functional effect 
of miR-22 as a novel regulator of cellular senescence in normal 
human and cancer cells and addressed the inhibitory role of 
miR-22 in tumor growth and metastasis, suggesting that miR-22–
induced senescence acts as a barrier to cancer progression   
in vitro and in vivo. Our study extends the current understanding JCB • VOLUME 193 • NUMBER 2 • 2011   418
Figure 6.  SIRT1, Sp1, and CDK6 are potentially involved in miR-22–mediated cellular senescence. (A) Representative growth curves corresponding to 
MDA-D3 cells transfected with cont siR or siRNAs against SIRT1, Sp1, and CDK6. Each value was determined in triplicate. (B) The histograms display the percent-
age of SA--gal–positive cells in MRC-5 and MDA-D3 cells at day 6 after siRNA transfection. (C–F) Western blot analysis was performed in those cells as 
indicated in each panel at 72 h after siRNA/miRNA transfection (C–E) or day 6 after infection (F). -actin was used as a loading control and the relative 
density of bands was densitometrically quantified. (G and H) SiHa cells were first transfected with miR-22 duplex and, 24 h later, sequentially transfected 
with expressing plasmids or empty vectors as indicated. Cell proliferation (G) and SA--gal (H) activity was evaluated at day 6 after miRNA transfection. 
Data in all the panels represent mean ± SEM (n = 3). *, P < 0.05; **, P < 0.01.419 miR-22 induces cellular senescence • Xu et al.
of SA-miRNAs in tumorigenesis by unraveling the role of miR-22 
in cellular senescence and tumor suppression. miRNAs present 
a mechanism in which genes involved in a variety of different sig-
naling pathways can be regulated simultaneously (He and Hannon, 
2004; Lafferty-Whyte et al., 2009). Not only does miR-22–induced 
senescence inhibit unlimited tumor cell proliferation, senescence 
morphological changes also suppress tumor cell motility and inva-
sion, partially because of enhanced actin stress fibers in cancer 
cells, indicating that the induction of senescence contributes to the 
suppression of tumor cell growth, invasion, and metastasis in vitro 
and in vivo.
Our study shows that miR-22 is differentially expressed 
in normal human and cancer cells. Consistent with our results, 
miR-22 dysregulation in cancer and human diseases has been 
documented in several miRNA profiling experiments. miR-22 is 
down-regulated in intrahepatic cholangiocarcinoma (Kawahigashi 
et al., 2009) and silenced in acute lymphoblastic leukemia (Li 
et al., 2010) and hepatocellular carcinoma (Calin et al., 2004) 
but up-regulated in osteoarthritis (Iliopoulos et al., 2008). These 
varying levels of miR-22 expression may suggest different re-
quirements for alterations in their target gene pathways. miR-22 
regulates a repertoire of cancer-related genes; however, there 
is no indication of the importance of miR-22 in tumorigenesis 
through targeting senescence-associated genes. In the present 
study, gain-of-function and loss-of-function phenotypes of 
miR-22 demonstrated the role of miR-22 as a positive regulator 
of cellular senescence and identified SIRT1, Sp1, and CDK6 as 
critical targets of miR-22 in the senescence signaling pathway.
Previous studies have documented that SIRT1, Sp1, and 
CDK6 might act on the p53 and/or pRb pathway. (Ota et al., 
2006; Ruas et al., 2007; Tapias et al., 2008; Brooks et al., 2009) 
SIRT1 plays an important role in the longevity and cellular   
senescence of most organisms through directly modulating the 
p16–pRb signaling pathway (Huang et al., 2008) as well as p53 
and other proteins (Solomon et al., 2006; Brooks and Gu, 2009). 
The Sp1 transcription factor regulates the expression of multi-
ple cell cycle genes, including the p53 and Sp1 gene itself 
(Koutsodontis et al., 2001; Tapias et al., 2008). CDK6 protein 
has been understood to phosphorylate pRB and delay senes-
cence (Ruas et al., 2007; Ohtani et al., 2009). Our study demon-
strated that miR-22 induced the dephosphorylation of pRB 
by targeting SIRT1 and CDK6. Collectively, we suppose that 
miR-22 regulates cellular senescence through connecting SIRT1, 
Sp1, and CDK6 to affect the pRb pathway and might coordinate 
p53 and other signaling pathways of cellular senescence in a 
cell type– and genetic context–dependent manner.
Figure 7.  Overexpression of miR-22 induces cell   
enlargement and inhibits cell invasion in vitro. 
(A)  Cell  morphology  area  and  actin  stress   
fiber  formation  (stained  with  phalloidin)  in   
miR-22–transfected SiHa cells were examined by 
confocal microscopy and compared with con-
trol cells. Enlarged images of the boxed area 
from  the  top  are  shown  in  the  bottom.  Bar,   
20 µm (top, left and right). The histogram shows 
that F-actin formation was quantified using the 
texture analysis, and F-actin SER Valley rep-
resented  occurrence  of  stress  fiber  structures 
within  cells.  (B)  Cell  size  distribution  (left),   
overall morphology area (middle), and per-
centage of cells in three groups of cell size 
(right) were calculated and analyzed by auto-
mated image analysis in SiHa cells. (C) Effect of 
miR-22 on SiHa and MDA-D3 cell invasion was 
measured by Matrigel invasion assay for 48 h, 
presented by quantitative determination of the 
number of invaded cells. Data in all the panels 
represent mean ± SEM (n = 3). *, P < 0.05.JCB • VOLUME 193 • NUMBER 2 • 2011   420
is no indication of miR-22 function in normal human cells. In our 
study, miR-22 is particularly up-regulated upon cellular senes-
cence in human fibroblasts and epithelial cells, and overexpres-
sion of miR-22 induced senescence phenotypes in these cells, 
indicating that miR-22 might emerge as the principal regulator 
that controls cell functions in physiological and pathophysio-
logical settings. However, it is obscure in the mechanism that   
controls the increased expression of miR-22 during senescence. 
We  attempted  stable  knockdown  of  miR-22  in  early-passage 
MRC-5 (Fig. 2 D) and IMR90 cells (unpublished data), which 
resulted in both of the cells seeming younger than untreated cells. 
Furthermore, we investigated how stable knockdown of miR-22 
affected late-passage MRC-5 cells. Our results demonstrated that 
those anti-22–infected presenescent MRC-5 cells appeared to be 
small, thin, and young with the decrease in cell morphology area 
and fewer SA--gal–positive cells (Fig. 2, C–F), indicating that 
inhibition of miR-22 is an obstacle for cells to undergo senes-
cence. Given our finding that miR-22 induces cellular senes-
cence  in  human  fibroblasts  in  vitro,  it  will  be  interesting  to 
determine whether miR-22 is involved in human aging in vivo.
The ability of miRNAs to affect many mRNAs is similar 
to the ability of transcription factors to regulate many promoters 
simultaneously. Recent studies demonstrate that miR-22 consti-
tutes a feedback loop with c-myc and MYCBP and forms a reg-
ulatory loop in the phosphatase and tensin homolog–AKT 
pathway (Iliopoulos et al., 2008; Pandey and Picard, 2009; Bar 
and Dikstein, 2010; Xiong et al., 2010). The human miR-22 
gene is located in a minimal loss of heterozygosity region on 
chromosome 17 close to p53 (Calin et al., 2004). We predict 
that miR-22 might induce complex changes and the extensive 
cooperation between miR-22 and p53 known to be involved in 
the senescence program, which remains to be elucidated.
miR-22 has been shown to be ubiquitously expressed in 
human cells and various tissues (Neely et al., 2006). Expression 
of miR-22 increases after the induction of stem cell differentia-
tion and in erythropoiesis, which indicates that it might have an 
important role in cell development and differentiation (Choong   
et al., 2007; Gangaraju and Lin, 2009). miR-22 is highly ex-
pressed in mammary progenitor cells, implicating its possible 
role in progenitor self-renewal (Ibarra et al., 2007). To date, there 
Figure  8.  Synthetic  miR-22  delivery  in-
duces cellular senescence in vivo and inhibits 
breast tumor growth and metastasis in vivo.  
(A  and  B)  Representative  fat  pad  orthotopic 
tumor (A) and selected organ (B) images of 
mice on day 46 after inoculation. Quantitation 
of bioluminescence emitted from the primary 
tumor (A) or whole body (B) of mice was pre-
sented as the mean ± SEM (n = 6). L, liver; 
K, kidney; Sp, spleen; Si, small intestine; St, 
stomach.  (C)  Relative  quantitation  of  miR-22 
level in primary tumor tissues was analyzed 
by  qRT-PCR.  Total  RNA  was  isolated  from 
five  10-µm-thick  optimal  cutting  temperature 
compound–embedded  frozen  tissue  sections. 
Expression level of miR-22 in miR-22–treated 
tumors was relative to that in cont miR–treated 
tumors set at 1. U6 was used as an internal 
normalization control. Data represent mean ± 
SEM (n = 5). (D and E) Representative histo-
chemical detection of SA--gal activity in vivo 
(D) and hematoxylin and eosin (HE) staining 
(E) in primary tumor on day 46 after inocula-
tion. Images were taken with light microscopy. 
Seven  independent  fields  were  chosen,  and 
the  percentage  of  SA--gal–positive  cells  is 
presented  in  the  histogram.  Data  represent 
mean ± SEM (n = 4). Bars, 50 µm. (F) Effect of 
miR-22 on cell proliferation in primary tumor   
tissues  was  evaluated  by  Ki-67  immuno-
staining. The histogram displays the percentage 
of Ki-67 labeling index in these groups. Data 
represent mean ± SEM (n = 3). *, P < 0.05;   
**, P < 0.01.421 miR-22 induces cellular senescence • Xu et al.
2–4 wk as senescent normal cells. MRC-5 (41–51 PDL) and 184hTERT 
(84–100 PDL) were used as young fibroblasts and immortalized epithe-
lial cells, respectively.
miRNA microarray
Total RNAs were harvested from young (42 PDL) and senescent (74 PDL) 
TIG-3 fibroblasts using the traditional acid guanidinium-phenol-chloroform 
extraction method and quantified with a spectrophotometer (NanoDrop; 
Thermo Fisher Scientific). Microarray analysis of miRNA expression was 
performed by both miRCURY LNA miRNA Array (Exiqon) and 3D-Gene   
microarray (Toray).
Real-time qPCR
Total RNA was extracted from the cells and tissues using the miRNeasy 
Mini kit (QIAGEN). The expression of miRNA was quantified by miRNA 
assays (TaqMan; Applied Biosystems). Real-time qRT-PCR was performed 
using a real-time PCR system (ABI StepOne and StepOnePlus; Applied Bio-
systems) and LightCycle 480 (Roche). Expression of miRNA was defined 
from the threshold cycle, and relative expression levels were calculated using 
the 2
Ct method after normalization with reference to the expression of 
U6 small nuclear RNA.
Transient miRNA/siRNA transfection and plasmid transfection
Hsa-miR-22 duplex and negative control were obtained from QIAGEN. 
siRNAs targeting SIRT1, Sp1, CDK6, and negative control siRNA were 
purchased from Invitrogen. Cells were transfected with 10 nM of either 
miRNA or siRNA (except as mentioned) using Lipofectamine RNAiMax   
(Invitrogen)  according  to  the  manufacturer’s  protocol.  Transfection  effi-
ciency under the conditions we adopted in this study was estimated to be 
>90% according to our observations made using a fluorescence-labeled 
double-stranded siRNA.
For rescue experiments, the expression plasmids used were pcDNA3.1-
SIRT1 (a gift from B. Marshall, Gladstone Institute, San Francisco, CA),   
pCMVneo-CDK6 (provided by S. Van den Heuvel, Utrecht University, Utrecht, 
Netherlands), and CMV-Sp1 (Addgene). These constructs contain the en-
coding region of mRNA but lack the 3-UTR of these genes. Cells were first 
transfected with miRNA in a 60-mm dish for 24 h and sequentially trans-
fected with 0.25 µg of plasmid DNA using Lipofectamine LTX Plus reagent 
(Invitrogen) according to the manufacturer’s protocol. The overexpression 
of SIRT1, Sp1, and CDK6 was confirmed by Western blotting. After a 24-h 
incubation, cells were seeded to 35-mm-diameter dishes and incubated for 
4 d until cell proliferation assay and SA--gal assay.
Lentivirus infection
Lentiviruses were generated by cotransfecting 0.9 µg of lentiviral vector 
(premiR-22, miRZip, anti–miR-22, or empty vectors; System Biosciences) and 
2.7 µg of packaging plasmid mix (1:1:1 for 0.9 µg pPACK-H1-GAG, 
pPACK-H1-Rev, and pVSV-G) in 293T cells using Lipofectamine LTX Plus re-
agent. Supernatants were collected 48 h after transfection, filtered through 
a 0.45-µm membrane, and directly used to infect cells. Cells were observed 
and images were acquired using a 10× objective with fluorescent micros-
copy (Axiovert 200M; Carl Zeiss) in combination with a camera (AxioCam; 
Carl Zeiss) and AxioVision software (Carl Zeiss) at room temperature.
Cell proliferation and SA--gal assay
For cell proliferation assay, 48 h after transfection or infection, 3–5 × 10
4 
cells were seeded in a series of 35-mm-diameter dishes and counted for the 
indicated days. For cytochemical and histochemical detection of SA--
gal activity, SA--gal staining was performed as described previously   
(Debacq-Chainiaux et al., 2009). SA--gal–positive cells were quantified 
by counting positive and negative cells at 100× magnification in at least 
five random independent fields. Pictures were taken with a 10× phase-
contrast objective on a light microscope (IMT-2; Olympus) with a camera 
using Image saver (AE-6905; ATTO) at room temperature.
Automated image acquisition
SiHa cells were seeded in a 96-well Viewplate (PerkinElmer) and trans-
fected with cont miR, miR-22, or miR-34a for 72 h. To measure cell size and 
F-actin, cells were fixed by 4% PFA and stained with the actin marker   
Rhodamine phalloidin (1:40; Invitrogen; provided by S. Kobayashi and   
H. Kishi, Yamaguchi University, Ube, Japan). For BrdU quantitative analy-
sis, cells were pulse labeled with 10 µM BrdU (Sigma-Aldrich) for 1 h at 
37°C, incubated with 5% CO2, and fixed by 70% ice-cold ethanol for 30 min 
at room temperature. Cells were treated with 2N HCl for 20 min, neutralized 
with 0.2 M Tris-HCl, pH 7.5, and permeabilized with 0.1% Triton X-100 
for 5 min, followed by the mouse anti-BrdU (1:200; Dako) and incubation for 
It has been reported that the regulation of proliferation 
signaling, cytoskeletal remodeling, and apoptosis survival path-
ways would logically be required to create the senescent cell 
phenotype, which can be regulated by SA-miRNAs with differ-
ential timings of these complex signaling cascades (Lafferty-
Whyte et al., 2009). These might give an explanation to the 
distinct  effects  of  miR-22  knockdown  on  cell  proliferation, 
morphology, and viability in various cells. We observed that 
actin stress fibers were enhanced in miR-22–transfected en-
larged cells (Fig. 7 A), whereas anti-22–infected cells appeared 
to be small and to have fewer stress fibers (unpublished data). 
Moreover, we noted that cytoskeleton arrangement and focal 
adhesion turnover occurred with differential timing in various 
anti-22–infected cells and thus might affect cell growth, adhe-
sion, and survival, which needs to be confirmed in a further 
study. In addition, miR-22 expression level is quite low in vari-
ous cancer cells, and permanent inhibition of miR-22 induced 
apoptosis, indicating that miR-22 kept to a certain level seems 
to be essential for cellular survival. It has been reported that 
miR-22 targets the phosphatase and tensin homolog and anti-22 
induces apoptosis in different cancer cells (Bar and Dikstein, 
2010; Liu et al., 2010), which is consistent with our results.
In this study, miR-22 inhibits the proliferation of human 
breast cancer metastasis cell lines (MDA-D3) both in vitro and 
in vivo through induction of genetic reprogramming of the se-
nescent pathway. Synthetic miR-22 injection significantly sup-
presses tumor growth and metastasis in a mouse model of breast 
cancer metastasis, indicating the therapeutic potential of miR-22 
in breast cancer metastasis. Currently, the emergence of new 
technologies that use synthetic miRNA mimics or anti–miRNA 
oligonucleotides holds great promise in clinical miRNA therapy 
(Garofalo and Croce, 2011). The first clinical trial for LNA- 
antimiR-122–based hepatitis C therapeutics was initiated after 
the successful therapeutic application of miR-122 antagonism 
in mice (Elmén et al., 2008), whereas the clinical application of 
synthetic miRNA mimics has not been reported. Synthetic miR-22 
mimic treatment in cancer will become a significant scientific 
and therapeutic challenge.
SA-miRNAs, such as miR-22, induce cellular senescence 
without causing apoptosis in cancer cells and subsequently result 
in tumor suppression (Fig. S5), providing a novel promising ap-
proach for the next generation of cancer therapy using nucleic 
acid biomedicine. We propose that permanent micromanaging 
of cancer cells by inducing senescence phenotypes using SA-
miRNAs may be novel and efficient for protecting recurrent 
cancer after conventional cancer treatments without causing 
side effects.
Materials and methods
Cell culture
MRC-5 cells were grown in DME/F12 (1:1, vol/vol) supplemented with 
SAP (0.2 mM serine, 0.1 mM aspartic acid, and 1.0 mM pyruvate). MDA-
MB-231-luc-D3H2LN is a luciferase-expressing cell line that was derived 
from MDA-MB-231 cells, maintained in RPMI1640 medium. Other human 
fibroblasts and cancer cells were cultured in DME. All media were supple-
mented with 10% FBS (vol/vol). HMEC184 cells were cultured in MEGM 
BulletKit (Takara Bio Inc.). TIG-3 (74–76 PDL), TIG-1 (63 PDL), TIG-114 
(51 PDL), MRC-5 (58–60 PDL), and HMEC184 (22 PDL) were cultured for   JCB • VOLUME 193 • NUMBER 2 • 2011   422
microscope stage for temperature equilibration. Time-laspe video record-
ings of live cells were performed for determination of cell motility. In brief, 
live cells from several nonoverlapping areas were recorded in 30-min or 1-h 
intervals over a period of 8–24 h using a CFl Plan Apo 10× objective with 
a fluorescence microscope (BIOREVO BZ-9000; KEYENCE) equipped with 
a motorized movable microscope stage. Recordings were stored as 8-bit 
680 × 512 pixel images. The microscope stage contained a thermostati-
cally controlled heating element and was surrounded by a Plexiglas incu-
bator, thereby ensuring that live specimens could be maintained at 37°C 
during recordings.
In vitro invasion assay
48 h after transfection, cells were resuspended in culture medium without 
serum and seeded at densities of 1.5 × 10
5 cells/well in 24-well Transwell 
inserts (8-µm pores; BD) coated with 50 µg Matrigel (BD). The lower cham-
ber was supplemented with a medium with 10% FBS. After 48 h of incuba-
tion, the cells on the upper surface were scraped off, whereas the invasive 
cells attached to the lower surface of the membrane inserts were fixed and 
stained with hematoxylin. The invading cells were observed and counted 
from nine images (including at least 2,000 cells) in three fields of three 
membranes using a 10× phase-contrast objective under light microscopy 
(U-PMTVC; Olympus) at room temperature.
Tumor imaging in vivo
5-wk-old female C.B17/Icr-scid (Scid/scid) mice (CLEA Japan, Inc.) were 
inoculated with MDA-MB-231-luc-D3H2LN cells into the fat pad on day 0 
as a 1:1 mixture of ECM gel complex and cells at 2 × 10
6 cells/50 µl/site. 
The hsa-miR-22 duplex and cont miR with RNA-jetPEI (Polyplus Transfec-
tion) complex at the ratio of 1:1 in a volume of 100 µl (20 µg/site) were 
injected intratumorally every other day from day 13 to 31 after inocula-
tion. The development of subsequent tumor growth and metastasis was 
monitored once a week by in vivo imaging. In brief, mice were injected 
with 150 mg/kg D-luciferin (Promega) intraperitoneally and imaged imme-
diately to count the photons from the whole bodies using the IVIS imaging 
system (Xenogen) according to the manufacturer’s instructions. 10 min later, 
photons from firefly luciferase were counted. Data were analyzed using 
LivingImage software (version 2.5; Xenogen).
Immunohistochemistry
Immunohistochemical staining was performed with anti–Ki-67 monoclonal 
antibody (1:50; Dako) after antigen retrieval by microwave treatment in citrate 
buffer, pH 6.0, and detection by a streptavidin–biotin peroxidase system 
using the LSAB kit (Dako). The sections were incubated with primary anti-
body at 4°C overnight. A labeling index percentage of Ki-67 was determined 
by examining at least 500 tumor cells at 200× magnification in three rep-
resentative and intensely stained areas using a 20× objective under light 
microscopy (U-PMTVC) at room temperature. The expression of Ki-67 was 
graded as high (>50% of positive cells) and low (<50% of positive cells).
Statistical analysis
Significance of differences between the treated samples and controls was 
determined by two-tailed t tests using Excel (Microsoft). P < 0.05 was con-
sidered statistically significant.
Online supplemental material
Fig. S1 shows the opposite effect of miR-22 overexpression and knock-
down on apoptosis in human cancer cells. Fig. S2 shows that miR-22 has 
no effect on the length of total telomere or G-tail in human cancer cells. 
Fig. S3 shows an examination of BrdU quantity analysis, cell morphology 
area, and F-actin formation by automated image analysis. Fig. S4 shows 
the images of cell motility observation in senescent fibroblasts and Lenti-
Pre22–infected MDA-D3 cells. Fig. S5 shows a scheme for the role of 
miR-22–induced senescence in cancer cells. Table S1 shows altered ex-
pression miRNAs identified by miRNA microarray function in cell growth 
and  tumorigenesis.  Table  S2  shows  PCR  primers  and  oligonucleotide 
sequences for each construct of miR-22 putative targets in luciferase re-
porter assay. Videos 1–4 show cell motility observation of young and 
senescent MRC-5 cells, Lenti-C, and Lenti-Pre22–infected MDA-D3 cells, 
respectively. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201010100/DC1.
We thank Maki Yoshida for her assistance with the invasion assay experi-
ments, Ryo Shioda (PerkinElmer, Japan) for his technical help with automated 
image acquisition, Sei Kobayashi and Hiroko Kishi (Yamaguchi University) for 
the provided reagents, and Anno Kumiko (Hiroshima University) and Takayuki 
Mizutani (IZM, Inc., Japan) for their technical support.
1 h. Cells were then stained with anti–mouse AF488 (1:500; Invitrogen). 
DAPI (1 µg/ml; Dojindo) images were used for nuclear recognition and cell 
counting. Images were acquired in a fully automated and unbiased man-
ner using a 10× objective with a spinning disk confocal microscope (Oper-
etta;  PerkinElmer)  at  room  temperature.  Eight  images  per  well  were 
collected to obtain a sufficient number of cells for reliable statistical analy-
sis. Image correction and analysis were performed using custom-designed 
image analysis software (Harmony; PerkinElmer). The histogram in Fig. 7 A 
shows that F-actin was quantified using the texture analysis by Harmony 
software (PerkinElmer), and F-actin SER Valley represented the occurrence 
of stress fiber structures within cells.
FACS analysis
48 h after transfection, cells were fixed in 70% ice-cold ethanol and stained 
with PBS containing 50 µg/ml propidium iodide and 100 µg/ml RNase A 
for DNA content analysis by flow cytometry analysis on a FACSCalibur 
system (BD). The percentage of cells in the various cell cycle phases was 
calculated using ModFitLT v2.0 software (Verity Software House).
Apoptosis assays
Cells were plated in an 8-well CultureSlide (BD), and apoptotic cells were 
detected with traditional or modified TUNEL assay using the DeadEnd Fluo-
rometric TUNEL System (Promega) according to the manufacturer’s proto-
col. In modified TUNEL assay, Cy5-dUTP (GE Healthcare) was substituted 
for fluorescein-dUTP in a standard TUNEL reaction to detect apoptotic cells 
of GFP-expressed cells. Images were acquired using a 40× objective with 
fluorescent microscopy (Axiovert 200M) in combination with a camera 
(AxioCam) and AxioVision software at room temperature.
Hybridization protection assay (HPA) and Southern blot analysis
Cells were plated in a 100-mm culture dish and transfected, and DNA was 
extracted with a traditional phenol-chloroform 72 h after transfection. The 
lengths of total telomere and G-tail were determined using Southern blot-
ting and HPA methods as described previously (Tahara et al., 2005).
Western blotting
72 h after transfection or at day 6 after infection, cells were homogenized 
in lysis buffer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 1% NP-40, 100 mM 
NaF,  0.2  mM  Na3VO4,  and  Complete  mini  protein  inhibitor  cocktail 
[Roche]). 30 µg of proteins in the total cell lysate was separated by SDS-
PAGE and transferred to polyvinylidene fluoride membrane. Antibodies to 
p53 (clone BP53-12; Millipore), phospho-Rb (ser807/811; Cell Signaling 
Technology), and -actin (Sigma-Aldrich) were purchased, and anti-CDK6 
(C-21), SIRT1 (H-300), and Sp1 (PEP2) antibodies were purchased from 
Santa Cruz Biotechnology, Inc. The secondary antibodies were HRP- 
conjugated anti–rabbit (NA 934V) and –mouse (NA 931V) antibodies (GE 
Healthcare). Immunoreactive bands were visualized using an ECL Plus kit (GE 
Healthcare), followed by exposure to x-ray film (RX-U; Fujifilm). The density 
of bands was densitometrically quantified using ImageJ (National Institutes 
of Health).
Luciferase reporter assay
The full-length 3-UTRs of human SIRT1 and Sp1 were amplified by PCR 
from genomic DNA and cloned at the SacI and XhoI sites into pmirGLO 
vector (Promega). The 3-UTR fragments of human CDK6 containing three 
putative miR-22 binding sites were also amplified from genomic DNA and 
cloned at the XhoI and SalI sites into pmirGLO vector. The sense and anti-
sense oligonucleotides for the putative miR-22 binding site at the 3-UTR of 
potential targets were annealed and cloned at the SacI and XbaI sites into 
pmirGLO vector. An internal NotI site was added to the oligonucleotides 
for clone confirmation. A positive control construct contains complete com-
plementary mature miR-22 sequence. PCR primers and oligonucleotide se-
quences for constructs are provided in Table S2. All the constructs were 
further confirmed by sequencing.
For luciferase activity analysis, each construct was cotransfected 
with miRNA duplex in a 96-well plate using DharmFECT Duo transfection 
reagent (Thermo Fisher Scientific) for 72 h, and luciferase assays were per-
formed with the Dual-Luciferase reporter system (Promega) according to the 
manufacturer’s instructions. Luminescent signal was quantified by luminom-
eter (Glomax; Promega), and each value from firefly luciferase construct 
was normalized by Renilla luciferase assay.
Cell motility observation by fluorescence microscopy
Cells were seeded in a 4-well 35-mm dish (Greiner Bio-One) at a density 
of 1,000 cells/well and grown for 48 h in culture medium. Before record-
ings were initiated, the multidishes were left for at least 30 min on the   423 miR-22 induces cellular senescence • Xu et al.
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